TUBA1A licenses APC/C-mediated mitotic progression to drive glioblastoma growth by inhibiting PLK3

FEBS Lett. 2023 Dec;597(24):3072-3086. doi: 10.1002/1873-3468.14764. Epub 2023 Nov 7.

Abstract

Glioblastoma (GBM) is the most common, aggressive, and chemorefractory primary brain tumor in adults. Identifying novel drug targets is crucial for GBM treatment. Here, we demonstrate that tubulin alpha 1a (TUBA1A) is significantly upregulated in GBM compared to low-grade gliomas (LGG) and normal tissues. High TUBA1A expression is associated with poor survival in GBM patients. TUBA1A knockdown results in mitotic arrest and reduces tumor growth in mice. TUBA1A interacts with the polo-like kinase 3 (PLK3) in the cytoplasm to inhibit its activation. This interaction licenses activation of the anaphase-promoting complex or cyclosome (APC/C) to ensure proper Foxm1-mediated metaphase-to-anaphase transition and mitotic exit. Overall, our findings demonstrate that targeting TUBA1A attenuates GBM cell growth by suppressing mitotic progression in a PLK3-dependent manner.

Keywords: Foxm1; Mitotic arrest; Polo-Like Kinase 3; TUBA1A; glioblastoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaphase
  • Anaphase-Promoting Complex-Cyclosome / genetics
  • Anaphase-Promoting Complex-Cyclosome / metabolism
  • Animals
  • Cell Cycle Proteins* / genetics
  • Cell Cycle Proteins* / metabolism
  • Glioblastoma* / drug therapy
  • Glioblastoma* / genetics
  • Humans
  • Metaphase
  • Mice
  • Mitosis
  • Polo-like Kinases
  • Protein Serine-Threonine Kinases / genetics
  • Tubulin
  • Tumor Suppressor Proteins

Substances

  • Anaphase-Promoting Complex-Cyclosome
  • Cell Cycle Proteins
  • PLK3 protein, human
  • Polo-like Kinases
  • Protein Serine-Threonine Kinases
  • TUBA1A protein, human
  • Tubulin
  • Tumor Suppressor Proteins
  • Tuba1a protein, mouse
  • Plk3 protein, mouse